A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors (NCT06209567) | Clinical Trial Compass
Active — Not RecruitingEarly Phase 1
A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors
United States11 participantsStarted 2024-01-05
Plain-language summary
The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Ability to understand and the willingness to sign (or their legally acceptable representative (LAR) must sign) a written informed consent document
* Adults ≥ 18 years old
* Suspicion for or histologically or cytologically confirmed and previously treated HGG or brain metastases from a primary extracranial malignancy
* Lesion size ≥ 1 cm (for the lesion to be biopsied)
* ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
* Planned to undergo biopsy/resection of brain lesion
Exclusion Criteria:
* Inability to undergo a PET scan (e.g., claustrophobia or noncompatible implant in case PET/MR is performed)
* Pregnant or nursing female. All women of childbearing potential must have a documented negative serum or urine pregnancy test \<1 week before study.
* Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Patients with severe allergy to both iodinated and gadolinium contrast.
What they're measuring
1
Assess range of tumor uptake of 68Ga-PSMA-11 in participants